For the quarter ending 2025-09-30, ALLR had -$1,100K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -2,806 | -5,052 |
| Depreciation and amortization | -21 | - |
| Common stock issued for services | -50 | -50 |
| Stock-based compensation | 132 | 303 |
| Impairment of intangible assets | 0 | - |
| Unrealized foreign exchange gains | 0 | 13 |
| Non-cash interest expense | 74 | 92 |
| Depreciation and amortization | - | 23 |
| Change in fair value of warrant and derivative liabilities | 0 | -1 |
| Deferred income taxes | 0 | 0 |
| Other current assets | -3 | 1 |
| Tax credit receivable | 53 | 839 |
| Prepaid expenses | 439 | 850 |
| Accounts payable | -3 | 436 |
| Accrued expenses and other liabilities | -324 | -2,322 |
| Income taxes payable | 0 | 7 |
| Net cash used in operating activities | -3,410 | -8,167 |
| Proceeds from atm sales of common stock, net of issuance costs | 0 | 11,143 |
| Net proceeds from sale of common stock and pre-funded warrant issuance | 2,451 | - |
| Proceeds from issuance of convertible redeemable series a preferred stock | 0 | - |
| Redemption of convertible redeemable series a preferred stock | 0 | - |
| Proceeds from convertible promissory notes and accrued interest, net of discount | 0 | 0 |
| Repayment of debt and promissory notes | 0 | 0 |
| Common stock repurchase | 141 | 2,565 |
| Net cash provided by financing activities | 2,310 | 8,578 |
| Net increase in cash and cash equivalents | -1,100 | 411 |
| Effect of exchange rate changes on cash | -1,949 | - |
| Cash and cash equivalents at beginning of period | 19,533 | - |
| Cash and cash equivalents at end of period | 16,895 | - |
Allarity Therapeutics, Inc. (ALLR)
Allarity Therapeutics, Inc. (ALLR)